In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

Conference call to discuss new data presented for duvakitug (Anti-TL1A) positive Phase 2b results at the 20th Annual Congress of the European ...

Shares of NYSE TEVA opened at $17.81 on Thursday. Teva Pharmaceutical Industries has a 12 month low of $11.62 and a 12 month high of $22.80. The company has a market cap of $20.17 billion, a P/E ...

Teva Pharmaceutical Industries Ltd. (TEVA) reported $4.23 billion in revenue for the quarter ended December 2024, representing a year-over-year decline of 5.1%. EPS of $0.71 for the same period ...

Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Sell-side analysts expect that Teva Pharmaceutical Industries Limited will post 2.62 ...

About Teva Pharmaceuticals Teva Pharmaceutical Industries Ltd. is a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to continue the momentum behind the ...

SOPA Images / Contributor / Getty Images Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 treatment for eye disorders.

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...